<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811317</url>
  </required_header>
  <id_info>
    <org_study_id>2007P-000101</org_study_id>
    <secondary_id>H-27207</secondary_id>
    <secondary_id>SPID#0813</secondary_id>
    <nct_id>NCT00811317</nct_id>
  </id_info>
  <brief_title>Closed-loop Glucose Control for Automated Management of Type 1 Diabetes</brief_title>
  <official_title>Closed-loop Glucose Control for Automated Management of Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University Charles River Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University Charles River Campus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that our integrated closed-loop glucose-control system can provide effective,
      tight, and safe blood glucose (BG) control in type 1 diabetes, thereby establishing the
      feasibility of closed-loop BG control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigates the utility of an integrated closed-loop glucose-control system for
      regulating BG in type 1 diabetic subjects. The closed-loop system utilizes sub-cutaneous
      infusion or insulin and glucagon under the control of a computer algorithm. The only inputs
      to the algorithm are the subject weight and BG values measured every five minutes. Subjects
      will undergo up to three 27 hour GCRC admissions during which they will consume three
      standardized meals. Subject may participate in up to two closed-loop visits (with different
      insulin lispro pharmacokinetic parameter settings in the control algorithm) and some subjects
      will participate in open-loop visits. During the closed-loop admission BG will be controlled
      by the closed-loop system. During the open-loop visit subjects will regulate their own BG in
      the usual function using their insulin pumps. A small group of non-diabetic subjects will
      undergo a single 27 hour GCRC admission during which they will eat the same standardized
      meals. During all admission BG will be measured every 5 minutes and blood will be collected
      for measurement of insulin and glucagon levels every 10 minutes. During the closed-loop
      admission of diabetic subjects and the single admission of non-diabetic subjects, three
      commercially available continuous glucose monitoring devices will be worn. The data from
      these devices will later be compared to reference BG data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Blood Glucose Over the Closed-loop Control Period</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent Within 70-180 mg/dl</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Hyperglycemia Following Each Meal</measure>
    <time_frame>After each of 3 meals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent in Hyperglycemia (BG&gt; 180 mg/dl) After Meals</measure>
    <time_frame>After each of 3 meals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Peak Post-prandial Hyperglycemias &lt; 180 mg/dl (ADA Target)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent With BG &lt; 70 mg/dl</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycemic Events</measure>
    <time_frame>24 hours</time_frame>
    <description>This outcome captures the number of hypoglycemic events that occurred throughout the entire study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nadir Blood Glucose Level for Each Hypoglycemic Event</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent With BG &gt; 180 mg/dl</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Insulin Dose</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon T-max</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to maximum peak glucagon concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Glucagon Dose</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Glucagon Levels</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Glucose and Glycemic Variability (MAGE) During Closed Loop Control in Diabetic Subjects Compared to the Comparable 24-hour Period the Day Prior to Admission as Measured by Navigator CGM Data</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Carbohydrate Interventions</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a Stable Glucose Response to Insulin Dosing</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a Stable Glucose Response to Insulin Dosing Around Idle Times Prior to Meals</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of the Continuous Glucose Monitor (CGM) Using Blood Glucose Measurement as the Standard</measure>
    <time_frame>24 hours</time_frame>
    <description>Measuring the mean absolute relative difference (MARD) between the blood glucose measurement and CGM glucose readings, on three different CGM devices: Dexcom, Guardian and Navigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Glucose and Glycemic Variability During Closed Loop Control in Diabetic Subjects Compared to the Comparable 24 Hour Period in Non-diabetic Subjects</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin and Glucagon Levels During the Closed-loop Admission as Compared to the Comparable 24 Hour Period During the Open Loop Admission of Diabetic Subjects</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity for Hypo- and Hyperglycemia of the CGM Devices Using the BG Measurement as the Standard</measure>
    <time_frame>24 hours</time_frame>
    <description>Mean absolute relative difference (MARD) of CGM and BG glucose readings in hypoglycemia (&lt; 70 mg/dl) and hyperglycemia (&gt;180 mg/dl) in three different CGM devices: Dexcom, Navigator and Guardian</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Set Point Using CGM Data as the Input to the Controller for Future Studies</measure>
    <time_frame>24 hours</time_frame>
    <description>The algorithm in the Bionic Pancreas must have a pre-specified target glucose it is trying to achieve in order to make dosing decisions. Using data from this study, investigators planned to determine what an appropriate glucose target should be for future studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin and Glucagon Levels During Closed Loop and Open Loop Admissions of Diabetic Subjects Compared to the Comparable 24 Hour Period During the Admission of Non-diabetic Subject</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Closed-loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 1 diabetic subjects under closed-loop blood glucose control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Closed-loop</intervention_name>
    <description>Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
    <arm_group_label>Closed-loop</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (type 1 diabetic subjects):

          -  Age 18 years or older

          -  Clinical type 1 diabetes for at least five years

          -  Otherwise healthy (mild chronic disease allowed if well controlled)

          -  Diabetes managed using an insulin infusion pump

          -  Body mass index (BMI) between 20 and 31

          -  Total daily dose (TDD) of insulin ≤ 1 U/kg and ≤ 100 U/day

          -  Post-prandial C-peptide &lt; 0.1 nmol/L at 90 minutes in a mixed meal (Sustacal)
             tolerance test by the DCCT method

          -  Hemoglobin A1c less than or equal to 8.5%

          -  Prescription medication regimen stable for at least 1 month

        Inclusion Criteria (non-diabetic subjects):

          -  Age 18 years or older

          -  No personal history of diabetes, impaired fasting glucose, or impaired glucose
             tolerance

          -  No personal history of pancreatic disease

          -  Not taking medication that may affect glucose, insulin, or glucagon dynamics

          -  Otherwise healthy (mild chronic disease allowed if well controlled)

          -  Body mass index (BMI) between 20 and 31

          -  Normal 75 g oral glucose tolerance test (fasting, 1 hour, and 2 hour measurements)

        Exclusion Criteria (all subjects):

          -  Unable to provide informed consent or are unable to comply with study procedures

          -  Current participation in another clinical trial

          -  Anemia (HCT or hemoglobin less than normal for sex)

          -  Elevated alanine aminotransferase (ALT &gt; 3 fold above upper limit of normal)

          -  Untreated or inadequately treated hyperthyroidism or hypothyroidism (abnormal TSH or
             free T4)

          -  Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the
             immediate future, or sexually active without use of contraception

          -  Progressive or proliferative diabetic retinopathy (subjects with mild,
             non-proliferative background retinopathy or stable disease previously treated with
             photocoagulation are not excluded).

          -  Renal insufficiency (creatinine clearance estimated by Cockcroft-Gault equation of ≤
             50 ml/min)

          -  Any known history or symptoms of coronary artery disease.

          -  Abnormal EKG

          -  Congestive heart failure

          -  History of TIA or stroke within preceding 6 months

          -  Acute illness or exacerbation of chronic illness at the time of the study procedure

          -  Change in medication regimen in the 30 days prior to enrollment

          -  History of seizures

          -  History of pheochromocytoma

          -  Abnormal plasma fractionated metanephrines

          -  History of adrenal disease or tumor

          -  History of pancreatic tumor, including insulinoma

          -  History of impaired gastric motility or gastroparesis requiring pharmacological or
             surgical treatment

          -  Current alcohol abuse (&gt; 3 drinks daily) or substance abuse (any use within the last 6
             months of illegal drugs)

          -  Severe mental illness (schizophrenia, bipolar disease, inadequately treated
             depression, or any psychiatric hospitalization in the last year)

          -  Impaired cognition or altered mental status.

          -  Hypertension (blood pressure &gt; 140/90) at the time of screening

          -  Use of medications that reduce gastric motility

          -  Electrically powered implants that might be susceptible to RF interference

          -  Use non-insulin injectable anti-diabetic medications, inhaled insulin, or oral
             anti-diabetic medications

          -  History of adverse reaction to glucagon (including allergy) besides nausea and
             vomiting.

          -  Established history of latex, adhesive, tape allergy, inadequate venous access,
             history of allergy to or intolerance of aspirin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Russell, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Damiano, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>El-Khatib FH, Jiang J, Gerrity RG, Damiano ER. Pharmacodynamics and stability of subcutaneously infused glucagon in a type 1 diabetic Swine model in vivo. Diabetes Technol Ther. 2007 Apr;9(2):135-44.</citation>
    <PMID>17425438</PMID>
  </reference>
  <reference>
    <citation>El-Khatib FH, Jiang J, Damiano ER. Adaptive closed-loop control provides blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic Swine. J Diabetes Sci Technol. 2007 Mar;1(2):181-92.</citation>
    <PMID>19888405</PMID>
  </reference>
  <reference>
    <citation>El-Khatib FH, Jiang J, Damiano ER. A feasibility study of bihormonal closed-loop blood glucose control using dual subcutaneous infusion of insulin and glucagon in ambulatory diabetic swine. J Diabetes Sci Technol. 2009 Jul 1;3(4):789-803.</citation>
    <PMID>20144330</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>December 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2008</study_first_posted>
  <results_first_submitted>April 18, 2017</results_first_submitted>
  <results_first_submitted_qc>October 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2017</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University</investigator_affiliation>
    <investigator_full_name>Edward R. Damiano</investigator_full_name>
    <investigator_title>Associate Professor of Biomedical Engineering</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>glucose</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>insulin</keyword>
  <keyword>glucagon</keyword>
  <keyword>counter-regulation</keyword>
  <keyword>closed-loop</keyword>
  <keyword>feedback</keyword>
  <keyword>control</keyword>
  <keyword>dual-infusion</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>automated</keyword>
  <keyword>artificial pancreas</keyword>
  <keyword>intensive insulin therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Closed-loop</title>
          <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Closed-loop</title>
          <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Blood Glucose Over the Closed-loop Control Period</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Average Blood Glucose Over the Closed-loop Control Period</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent Within 70-180 mg/dl</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent Within 70-180 mg/dl</title>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Hyperglycemia Following Each Meal</title>
        <time_frame>After each of 3 meals</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Hyperglycemia Following Each Meal</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.7" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.7" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.5" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent in Hyperglycemia (BG&gt; 180 mg/dl) After Meals</title>
        <time_frame>After each of 3 meals</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent in Hyperglycemia (BG&gt; 180 mg/dl) After Meals</title>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Peak Post-prandial Hyperglycemias &lt; 180 mg/dl (ADA Target)</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Peak Post-prandial Hyperglycemias &lt; 180 mg/dl (ADA Target)</title>
          <units>percentage of blood glucose measurements</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent With BG &lt; 70 mg/dl</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent With BG &lt; 70 mg/dl</title>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hypoglycemic Events</title>
        <description>This outcome captures the number of hypoglycemic events that occurred throughout the entire study</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hypoglycemic Events</title>
          <description>This outcome captures the number of hypoglycemic events that occurred throughout the entire study</description>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nadir Blood Glucose Level for Each Hypoglycemic Event</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Nadir Blood Glucose Level for Each Hypoglycemic Event</title>
          <units>mg/dl</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Event 1 of 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Event 2 of 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent With BG &gt; 180 mg/dl</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent With BG &gt; 180 mg/dl</title>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Insulin Dose</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Total Insulin Dose</title>
          <units>u/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon T-max</title>
        <description>Time to maximum peak glucagon concentration</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon T-max</title>
          <description>Time to maximum peak glucagon concentration</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Glucagon Dose</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Total Glucagon Dose</title>
          <units>mcg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Glucagon Levels</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucagon Levels</title>
          <units>microgram/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Glucose and Glycemic Variability (MAGE) During Closed Loop Control in Diabetic Subjects Compared to the Comparable 24-hour Period the Day Prior to Admission as Measured by Navigator CGM Data</title>
        <time_frame>24 hours</time_frame>
        <population>Navigator CGM data from the day prior to admission was not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Average Glucose and Glycemic Variability (MAGE) During Closed Loop Control in Diabetic Subjects Compared to the Comparable 24-hour Period the Day Prior to Admission as Measured by Navigator CGM Data</title>
          <population>Navigator CGM data from the day prior to admission was not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Carbohydrate Interventions</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Carbohydrate Interventions</title>
          <units>number of interventions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving a Stable Glucose Response to Insulin Dosing</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Stable Glucose Response to Insulin Dosing</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving a Stable Glucose Response to Insulin Dosing Around Idle Times Prior to Meals</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Stable Glucose Response to Insulin Dosing Around Idle Times Prior to Meals</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy of the Continuous Glucose Monitor (CGM) Using Blood Glucose Measurement as the Standard</title>
        <description>Measuring the mean absolute relative difference (MARD) between the blood glucose measurement and CGM glucose readings, on three different CGM devices: Dexcom, Guardian and Navigator</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy of the Continuous Glucose Monitor (CGM) Using Blood Glucose Measurement as the Standard</title>
          <description>Measuring the mean absolute relative difference (MARD) between the blood glucose measurement and CGM glucose readings, on three different CGM devices: Dexcom, Guardian and Navigator</description>
          <units>percent absolute difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Navigator CGM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.94" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dexcom CGM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.55" spread="20.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guardian CGM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.04" spread="15.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Glucose and Glycemic Variability During Closed Loop Control in Diabetic Subjects Compared to the Comparable 24 Hour Period in Non-diabetic Subjects</title>
        <time_frame>24 hours</time_frame>
        <population>This outcome was not analyzed. There were no experiments in non-diabetic subjects that we were able to make a comparison with</population>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Average Glucose and Glycemic Variability During Closed Loop Control in Diabetic Subjects Compared to the Comparable 24 Hour Period in Non-diabetic Subjects</title>
          <population>This outcome was not analyzed. There were no experiments in non-diabetic subjects that we were able to make a comparison with</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin and Glucagon Levels During the Closed-loop Admission as Compared to the Comparable 24 Hour Period During the Open Loop Admission of Diabetic Subjects</title>
        <time_frame>24 hours</time_frame>
        <population>This outcome was not analyzed. There were no open loop experiments in diabetic subjects that we were able to make a comparison with</population>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin and Glucagon Levels During the Closed-loop Admission as Compared to the Comparable 24 Hour Period During the Open Loop Admission of Diabetic Subjects</title>
          <population>This outcome was not analyzed. There were no open loop experiments in diabetic subjects that we were able to make a comparison with</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity for Hypo- and Hyperglycemia of the CGM Devices Using the BG Measurement as the Standard</title>
        <description>Mean absolute relative difference (MARD) of CGM and BG glucose readings in hypoglycemia (&lt; 70 mg/dl) and hyperglycemia (&gt;180 mg/dl) in three different CGM devices: Dexcom, Navigator and Guardian</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity for Hypo- and Hyperglycemia of the CGM Devices Using the BG Measurement as the Standard</title>
          <description>Mean absolute relative difference (MARD) of CGM and BG glucose readings in hypoglycemia (&lt; 70 mg/dl) and hyperglycemia (&gt;180 mg/dl) in three different CGM devices: Dexcom, Navigator and Guardian</description>
          <units>percent absolute difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dexcom &lt; 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.90" spread="11.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Navigator &lt; 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.64" spread="16.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guardian &lt; 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.46" spread="23.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dexcom &gt; 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.28" spread="15.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Navigator &gt; 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.41" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guardian &gt; 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.71" spread="16.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Set Point Using CGM Data as the Input to the Controller for Future Studies</title>
        <description>The algorithm in the Bionic Pancreas must have a pre-specified target glucose it is trying to achieve in order to make dosing decisions. Using data from this study, investigators planned to determine what an appropriate glucose target should be for future studies.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Set Point Using CGM Data as the Input to the Controller for Future Studies</title>
          <description>The algorithm in the Bionic Pancreas must have a pre-specified target glucose it is trying to achieve in order to make dosing decisions. Using data from this study, investigators planned to determine what an appropriate glucose target should be for future studies.</description>
          <units>mg/dl</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin and Glucagon Levels During Closed Loop and Open Loop Admissions of Diabetic Subjects Compared to the Comparable 24 Hour Period During the Admission of Non-diabetic Subject</title>
        <time_frame>24 hours</time_frame>
        <population>This outcome was not analyzed. There were no experiments in non-diabetic subjects that we were able to make a comparison with</population>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop</title>
            <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin and Glucagon Levels During Closed Loop and Open Loop Admissions of Diabetic Subjects Compared to the Comparable 24 Hour Period During the Admission of Non-diabetic Subject</title>
          <population>This outcome was not analyzed. There were no experiments in non-diabetic subjects that we were able to make a comparison with</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Closed-loop</title>
          <description>Type 1 diabetic subjects under closed-loop blood glucose control
Closed-loop: Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Russell</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6177261848</phone>
      <email>sjrussell@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

